NEWS & EVENTS
Novartis inks $2.1b endocyte buyout
NOVARTIS INKS $2.1B ENDOCYTE BUYOUT Novartis has struck a $2.1 billion (€1.8 billion) deal to acquire Endocyte. The deal caps off a whirlwind year for Endocyte, which licensed the cancer drug that caught Novartis’ eye for $12 million just 12 months ago. Endocyte was...
60th ash annual meeting and exposition
60TH ASH ANNUAL MEETING AND EXPOSITION National Search Associates is thrilled to have ASH in our hometown of San Diego CA this year. Events like ASH present a great opportunity for you to expand your network and potentially link up with other executives in your field....
In memoriam – Susan Weinstock
IN MEMORIAM – SUSAN WEINSTOCK Susan Weinstock: Forever in our hearts and always in the sunsets… It is with great sadness that we announce publicly the passing of our beloved colleague, and senior recruiter, Susan Weinstock. Susan passed unexpectedly from...
Promotions & new hires at national search associates
NATIONAL SEARCH AT ASCO Congratulations to Chelsea Brunetti & Eric Lona! They were recently promoted to Associate Director in January 2018. Both have placed a number of candidates in small and large biotech pharmaceutical companies for a number of years. They will...
National search associates successfully recruits ceo for legend biotech: yuan xu
NATIONAL SEARCH AT ASCO Nathan Hipp, VP at National Search Associates, collaborated with Legend Biotech to help them identify and hire their first CEO, marking an important milestone for the newly minted CAR-T biotech. Yuan Xu was previously Sr. Vice President...
New, high-impact studies to be featured at world’s largest clinical cancer research meeting
NEW, HIGH-IMPACT STUDIES TO BE FEATURED AT WORLD’S LARGEST CLINICAL CANCER RESEARCH MEETING The 2018 Annual Meeting will take place June 1-5 in Chicago and will bring more than 32,000 oncology professionals from around the world. The theme of this year’s conference is...
Novartis enters agreement to acquire avexis inc. For usd 8.7 bn
NOVARTIS ENTERS AGREEMENT TO ACQUIRE AVEXIS INC. FOR USD 8.7 BN Novartis announced they will merge with AveXis Inc. for 218 per share or a total of 8.7 billion in cash, this transaction was unanimously approved by Boards of both companies. AveXis has ongoing clinical...
Johnson & Johnson’s Darzalex Ambitions Take A Hit With Scrapped I-o Trials
JOHNSON & JOHNSON’S DARZALEX AMBITIONS TAKE A HIT WITH SCRAPPED I-O TRIALS J&J partners with Genmab announced that they will stop studies of Darzalex in combination with anti-pd-l1, since it failed to show benefit. This prompted Janssen to discontinue phase...